Promega-SABiosciences Agreement Enables the Most Sensitive Tools for Pathway Analysis
MADISON, WISCONSIN (August 11, 2009)
Promega and SABiosciences will combine their offerings to provide the most sensitive tools for interrogating specific cellular pathways via transcription factor reporters. Under the new agreement Promega recombinant firefly luciferase luc2 gene and a humanized Renilla luciferase (hRluc) gene- the ‘dual luciferases’- will serve as one key reporter system for SABiosciences pathway reporter assays under the Cignal™ moniker.
Cignal transcription reporters from SABiosciences offer the widest selection of pathway activity assays in the world, featuring more than 40 pathway reporters available in both DNA construct and viral particle formats. “We are pleased to include Promega’s recombinant firefly and humanized Renilla luciferases as reporters in our product lines. They provide the necessary levels of sensitivity for studying the effects of drugs or genetic perturbations on many interesting and biologically relevant cell types.” said Dave Martz, VP of Sales and Marketing at SABiosciences.
The Cignal products with Promega luciferase technology are currently available in tube and plate formats for multiple pathways of biological interest.
About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000
products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human
identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global
distributors. For more information about Promega, visit www.promega.com.
These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the
new products page or the specific product or application area.
For more information about a new release article or about Promega in general, contact Penny Patterson at 1-608-274-4330 or complete this
form.